2024
Understanding and overcoming resistance to immunotherapy in genitourinary cancers
Evans S, Jani Y, Jansen C, Yildirim A, Kalemoglu E, Bilen M. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biology & Therapy 2024, 25: 2342599. PMID: 38629578, PMCID: PMC11028033, DOI: 10.1080/15384047.2024.2342599.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsB7-H1 AntigenHumansImmunotherapyNeoplasmsNivolumabUrogenital NeoplasmsConceptsImmune checkpoint inhibitorsResistance to immunotherapyImmunotherapy resistanceTargeted therapyGenitourinary (GU) cancersCombined immune checkpoint inhibitorsIntroduction of novel immunotherapiesMechanisms of immunotherapy resistanceOvercome resistance to immunotherapyCancer cellsHost immune profileResponse to immunotherapyNovel targeted therapiesImmune system's rolePredictors of responseAttack cancer cellsImmune system's abilityStandard of careCheckpoint inhibitorsSequential therapyNovel immunotherapiesCombination therapyTreatment failureGU cancersTreatment landscapeImpact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis
Patel J, Woo Y, Draper A, Jansen C, Carlisle J, Innominato P, Lévi F, Dhabaan L, Master V, Bilen M, Khan M, Lowe M, Kissick H, Buchwald Z, Qian D. Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis. Journal For ImmunoTherapy Of Cancer 2024, 12: e008011. PMID: 38531662, PMCID: PMC10966813, DOI: 10.1136/jitc-2023-008011.Peer-Reviewed Original ResearchConceptsInfusions of immune checkpoint inhibitorsMetastatic renal cell carcinomaProgression-free survivalOverall survivalRenal cell carcinomaCell carcinomaInternational Metastatic RCC Database Consortium risk scoreAssociated with longer progression-free survivalLung cancerGroup BGroup ATime of ICI initiationLonger progression-free survivalNon-small cell lung cancerMultivariable Cox proportional hazards regressionImmune checkpoint inhibitorsPretreatment lactate dehydrogenaseCell lung cancerCox proportional hazards regressionAdaptive immune responsesProportional hazards regressionMulticenter cohort analysisCheckpoint inhibitorsICI initiationMetastatic melanomaEstablished and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma
Jani Y, Jansen C, Gerke M, Bilen M. Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma. Immunotherapy 2024, 16: 405-426. PMID: 38264827, DOI: 10.2217/imt-2023-0267.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCell carcinomaImmune checkpoint inhibitorsBiomarker of immunotherapyRisk of adverse eventsSignificant side effectsCheckpoint inhibitorsDevelopment of biomarkersAdverse eventsImmunotherapyTherapeutic efficacySide effectsPatientsClinical biomarkersPatient's diseaseTherapeutic biomarkersClinician's abilityBiomarkersCarcinomaPatient careImproving clinicians' abilityEfficacy
2020
Considerations for cancer immunotherapy biomarker research during COVID-19
Carlisle J, Jansen C, Bilen M, Kissick H. Considerations for cancer immunotherapy biomarker research during COVID-19. Endocrine Related Cancer 2020, -1: c1-c8. PMID: 32508308, PMCID: PMC7385701, DOI: 10.1530/erc-20-0187.Peer-Reviewed Original Research
2018
The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer
Jansen C, Prokhnevska N, Kissick H. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer. Urologic Oncology Seminars And Original Investigations 2018, 37: 543-555. PMID: 30446449, PMCID: PMC6513714, DOI: 10.1016/j.urolonc.2018.10.011.Peer-Reviewed Original Research